Access
This article is part of Nature's premium content.
Published online 2 June 2009 | Nature | doi:10.1038/news.2009.536
News
Drug giants unite to develop cancer therapy
Merck and AstraZeneca collaboration could launch a new trend — if their work yields results.
An unusual collaboration between two pharmaceutical giants could herald a welcome change in how cancer therapies are developed, cancer researchers say.
On 1 June, AstraZeneca, based in London, and Merck & Co.
To read this story in full you will need to login or make a payment (see right).
Comments
Reader comments are usually moderated after posting. If you find something offensive or inappropriate, you can speed this process by clicking 'Report this comment' (or, if that doesn't work for you, email webadmin@nature.com). For more controversial topics, we reserve the right to moderate before comments are published.
All the gene mutation or amplification stuides can tell us is whether or not cells are potentially susceptible to this mechanism of attack. They don't tell you if one drug is better or worse than some other drug which may target this. Targeted drugs are poorly-predicted by measuring the ostansible targets, but can be well-predicted by measuring the effect of a targeted drug(s) on the "function" of live cells.